Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first-in-human

- PMLiVE

Innovative Trials nominates Eloise Moffett as New VP of Commercial

Eloise Moffett joins Innovative Trials as New Vice President of Commercial to drive business growth globally

Innovative Trials

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Dupixent is now the first and only targeted medicine in the EU for this patient population

- PMLiVE

Kate Shaw comments the appointment of an independent review on clinical trials in the UK.

The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five...

Innovative Trials

Patient Recruitment: Think Global, Act Local

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients - and therefore more robust...

Innovative Trials

EU flag

European Commission grants AstraZeneca three new approvals

The indications are for adults with liver and lung cancers, and chronic lymphocytic leukaemia

- PMLiVE

UK government commissions independent review into clinical trials

The last five years have seen a 44% drop in commercial clinical trial recruitment in the UK

EU flag

EC approves first gene therapy for adults with haemophilia B

Typically, haemophilia B patients must adhere to strict, lifelong IV infusion schedules

EU flag

EC approves UCB’s Fintepla to treat severe form of epilepsy

Lennox-Gastaut syndrome affects around two in 10,000 people in the EU and usually begins in early childhood

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

This makes Dupixent the first and only targeted medicine indicated for this condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links